# Retrospective analysis of efficacy and safety of recombinant human Rh-endostatinstatin combined with concurrent radiotherapy for cervical cancer

## TL;DR

This study found that combining a drug called Rh-endostatin with radiotherapy improved outcomes for cervical cancer patients compared to radiotherapy alone.

## Contribution

The novel contribution is demonstrating the clinical benefits and safety profile of Rh-endostatin combined with radiotherapy in cervical cancer treatment.

## Key findings

- The observation group had a significantly higher complete response (CR) rate compared to the control group.
- The observation group showed a higher HPV conversion rate and better immune marker changes after treatment.
- The combination therapy had fewer nausea and vomiting side effects but more neutropenia and hypertension compared to radiotherapy alone.

## Abstract

Retrospective study and analysis of the safety and efficacy of Rh-Rh-endostatinstatin combined with simultaneous radiotherapy in the treatment of cervical cancer.

A retrospective study was used to enroll cervical cancer patients who received Rh-endostatin combined with simultaneous radiotherapy (observation group) or radiotherapy alone (control group) from January 2019 to December 2022 in the Affiliated Hospital of Hebei University, and RECIST 1.1 criteria were used to evaluate the recent efficacy, and the WHO Adverse Reaction Scale for Anti-cancer Drugs to evaluate the toxic and side effects.

The difference between PR, SD, PD, ORR and DCR of the two groups was not statistically significant(P>0.05), and the CR of the observation group was significantly higher than that of the control group(P<0.05). The proportion of neutropenia, hypertension, arrhythmia, hemoglobin reduction in the observation group was significantly higher than that in the control group, and the proportion of nausea and vomiting was significantly lower than that in the control group(P<0.05), and there was no significant difference in other adverse reactions(P>0.05). After intervention, the CD3+, CD3-CD19+, CD16+CD56+, CEA, CY211 of both groups were significantly lower than before treatment(P<0.05). After treatment, CD3+, CD3-CD19+, CD16+CD56+ were significantly higher in the observation group than in the control group, and WBC and PLT were significantly lower than before treatment(P<0.05). The HPV conversion rate of the observation group was significantly higher than that of the control group(P<0.05).

Our finding revealed that Rh-endostatinstatin combined with simultaneous radiotherapy showed better clinical outcomes and favorable toxic profile than that of radiotherapy alone in the treatment of cervical cancer.